NURIX THERAPEUTICS IN
22.00
08-October-24 14:59:59
15 minutes delayed
Stocks
+0.46
+2.14%
Today's range
21.30 - 22.72
ISIN
N/A
Source
NASDAQ
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences
09 Mar 2022 15:01:00 By Nasdaq GlobeNewswire
-
10 Feb 2022 15:01:00 By Nasdaq GlobeNewswire
-
27 Jan 2022 15:01:00 By Nasdaq GlobeNewswire
-
Nurix Therapeutics Advances Clinical and Preclinical Pipeline and Outlines 2022 Catalysts
10 Jan 2022 06:00:03 By Nasdaq GlobeNewswire
-
Nurix Therapeutics to Present at 40th Annual J.P. Morgan Healthcare Conference
03 Jan 2022 15:01:00 By Nasdaq GlobeNewswire
-
12 Nov 2021 06:09:00 By Nasdaq GlobeNewswire
-
12 Nov 2021 06:07:00 By Nasdaq GlobeNewswire
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences
09 Nov 2021 15:01:01 By Nasdaq GlobeNewswire
-
26 Oct 2021 15:02:00 By Nasdaq GlobeNewswire
-
Nurix Therapeutics to Participate in the 4th Annual Targeted Protein Degradation Summit
21 Oct 2021 06:00:01 By Nasdaq GlobeNewswire
-
14 Oct 2021 15:02:00 By Nasdaq GlobeNewswire
-
Nurix Therapeutics Expands its Board of Directors with the Addition of Two Industry Leaders
30 Sep 2021 06:00:00 By Nasdaq GlobeNewswire
-
13 Jul 2021 15:01:00 By Nasdaq GlobeNewswire
-
21 Jun 2021 15:01:00 By Nasdaq GlobeNewswire
-
02 Jun 2021 06:00:01 By Nasdaq GlobeNewswire
-
Nurix Therapeutics Appoints Industry Leader Clay Siegall, Ph.D., to its Board of Directors
01 Jun 2021 15:00:00 By Nasdaq GlobeNewswire
-
21 May 2021 06:00:00 By Nasdaq GlobeNewswire
-
Nurix Therapeutics to Participate in Upcoming Investor Conferences
11 May 2021 06:00:01 By Nasdaq GlobeNewswire